Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Derangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F.

Cancer Immunol Res. 2019 Dec;7(12):1958-1969. doi: 10.1158/2326-6066.CIR-19-0228. Epub 2019 Oct 14.

PMID:
31611243
2.

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C.

J Immunother Cancer. 2019 Jun 25;7(1):160. doi: 10.1186/s40425-019-0634-9.

3.

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F.

Oncoimmunology. 2019 Jan 22;8(4):e1564505. doi: 10.1080/2162402X.2018.1564505. eCollection 2019.

4.

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.

Cotte AK, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros JP, Hillon P, Ghiringhelli F, Delmas D.

Nat Commun. 2018 Jan 22;9(1):322. doi: 10.1038/s41467-017-02732-5.

5.

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F.

Nat Commun. 2017 Dec 12;8(1):2085. doi: 10.1038/s41467-017-01070-w.

6.

Trifluridine/Tipiracil combined to oxaliplatin sensitizes microsatellite stable colorectal cancer to anti-PD-1 blockade.

Limagne E, Nuttin L, Spill A, Thibaudin M, Derangere V, Cattan V, Bruno A, Amellal N, Ghiringhelli F.

Ann Oncol. 2017 Jun;28 Suppl 3:iii90. doi: 10.1093/annonc/mdx261.254. No abstract available.

7.

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F.

Cell Rep. 2017 Apr 25;19(4):746-759. doi: 10.1016/j.celrep.2017.04.004.

8.

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

Ladoire S, Derangère V, Arnould L, Thibaudin M, Coudert B, Lorgis V, Desmoulins I, Chaix M, Fumoleau P, Ghiringhelli F.

Ann Pathol. 2017 Feb;37(1):133-141. doi: 10.1016/j.annpat.2016.12.012. Epub 2017 Jan 31. Review. French.

PMID:
28159406
9.

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F.

Cancer Res. 2016 Sep 15;76(18):5241-52. doi: 10.1158/0008-5472.CAN-15-3164. Epub 2016 Aug 5.

10.

Human ectonucleotidase-expressing CD25high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions.

Thibaudin M, Chaix M, Boidot R, Végran F, Derangère V, Limagne E, Berger H, Ladoire S, Apetoh L, Ghiringhelli F.

Oncoimmunology. 2015 Jul 6;5(1):e1055444. eCollection 2016.

Supplemental Content

Loading ...
Support Center